Merck & Co., Inc. (FRA:6MK)
Germany · Delayed Price · Currency is EUR 75.00
-1.30 (-1.70%)
At close: Oct 23, 2025
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
€732,014
Profits / Employee
€188,780
Market Cap
188.46B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
| Siemens Healthineers AG | 72,000 |
Merck & Co. News
- 15 hours ago - eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience - PRNewsWire
- 16 hours ago - These low-risk stocks could be a profitable answer to this volatile earnings season - Market Watch
- 19 hours ago - Merck (MRK) Gains FDA Priority Review for Keytruda Combinations in Bladder Cancer - GuruFocus
- 20 hours ago - Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025 - Business Wire
- 20 hours ago - FDA Grants Priority Review For Merck's KEYTRUDA And KEYTRUDA QLEX SBLAs In MIBC - Nasdaq
- 21 hours ago - FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer - Business Wire
- 1 day ago - Merck & Co Unusual Options Activity - Benzinga
- 2 days ago - Merck (MRK) Collaborates with Flare Therapeutics in Cancer Treatment Study - GuruFocus